TCT 2023 | SWISS-APERO: One-Year Events After Left Atrial Appendage Closure with Amulet or Watchman FLX Device

It has been observed that the persistence of an opening in the left atrial appendage after percutaneous closure (LAAC) is associated with a higher risk of embolic events. Among the most commonly used devices for left atrial appendage closure are the Watchman FLX and Amulet devices. This study, known as SwissApero, represents the first randomized trial directly comparing these two devices.

TCT 2023 | Estudio WATCH-TAVR

The main finding of this study, as revealed by initial angiography follow-up, was that both devices achieved similar sealing at 45 days. This predefined analysis compared patency after left atrial appendage closure and presence of device-related thrombi (DRT) at 13 months of follow-up.

Researchers randomized a total of 221 patients, of which n=84 completed the follow-up with the Amulet device, and n=80 with the Watchman FLX. According to tomographic results at 13 months, left atrial appendage patency was 53.6% in the Amulet group and 48.8% in the Watchman FLX group (hazard ratio [HR], 1.10 [95% confidence interval (CI), 0.81-1.48]; p=0.537). Regarding the presence of DRT, it was recorded as 1.2% in the Amulet group and 1.3% in the Watchman FLX group (HR, 0.95 [95% CI, 0.06-14.97]; p=0.972).

In terms of clinical efficacy, there were no significant differences in the analyzed outcomes, including the composite of cardiovascular death, disabling stroke, or systemic embolism (HR, 0.91 [95% CI, 0.39-2.14]; p=0.829), mortality (HR, 1.19 [95% CI, 0.53-2.66]; p=0.671), or stroke (HR, 0.75 [95% CI, 0.17-3.35]; p=0.706).

Read also: TCT 2023 | The WATCH-TAVR Study.

In summary, the authors conclude that, among patients who underwent percutaneous left atrial appendage closure, both left atrial appendage patency and presence of device-related thrombi were very similar between the two compared groups, and there were no significant differences in the evaluated clinical outcomes.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Presented by Roberto Galea in Late-Breaking Clinical Trials at TCT 2023, San Francisco, October 23, 20232023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...